Hydroxychloroquine for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have IgA nephropathy confirmed by a kidney biopsy (any time in the past)
- Your last kidney biopsy showed at least one sign of active damage
- Your urine protein level is high (albumin/creatinine ratio over 300 mg/g)
- You are already taking two kidney-protecting medicines (RAAS blocker and SGLT2 inhibitor) for at least 1–3 months
- You are not pregnant or breastfeeding, and you and your partner will use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new medicine called finerenone can help people with IgA nephropathy, a kidney disease. You may be able to join if you are already on blood pressure medications, your kidney function is at a certain level, and you haven't needed immune-suppressing drugs recently.
This trial tests whether mycophenolate mofetil, an immunosuppressant drug, can reduce protein in the urine of people with IgA nephropathy that hasn't responded to other treatments. It aims to help slow down kidney damage.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This study tests whether a new drug called BHV-1400 can slow down or help IgA nephropathy, a condition where the immune system damages the kidneys. You'll be monitored to see if the drug is safe and effective for you.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.